Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® (Symb NIS)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 20, 2007
Last updated: June 8, 2009
Last verified: June 2009
The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Condition Phase
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Further study details as provided by AstraZeneca:

Enrollment: 310
Study Start Date: April 2007
Study Completion Date: November 2007
Chinese asthma patient prescribed Symbicort® Turbuhaler®


Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Natural History, longitudinal, defined population

Inclusion Criteria:

  1. Provision of informed consent
  2. Asthmatics who has been prescribed Symbicort according to physician's judgement
  3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

  1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
  2. No previous enrolment in the present study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00532922

China, Anhui
Research Site
Hefel, Anhui, China
China, Fujian
Research Site
Fuzhou, Fujian, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
China, Henan
Research Site
Zhengzhou, Henan, China
China, Hubei
Research Site
Wuhan, Hubei, China
China, Hubel
Research Site
Wuhan, Hubel, China
China, Jiangsu
Research Site
Nanjong, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
China, Liaoning
Research Site
Shenyand, Liaoning, China
China, Shandong
Research Site
Qingdao, Shandong, China
China, Shanxi
Research Site
Taiyuan, Shanxi, China
Research Site
Xi'an, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Zhejiang
Research Site
Wenzhou, Zhejiang, China
Research Site
Beijing, China
Research Site
Chongqing, China
Research Site
Hangzhou, China
Research Site
Shanghai, China
Sponsors and Collaborators
Principal Investigator: Zhou Xin Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Principal Investigator: Hong Jianguo Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  More Information Identifier: NCT00532922     History of Changes
Other Study ID Numbers: NIS-RCN-SYM-2006/1
Study First Received: September 20, 2007
Last Updated: June 8, 2009

Additional relevant MeSH terms:
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents processed this record on May 23, 2017